3QFY2024 gross profit surged by 12% y-o-y to RMB753 million while 9MFY2024 gross profit increased by 6% y-o-y to RMB2.69 billion. Gross profit margin for the 9MFY2024 rose by 4 percentage points y-o-y to 48% due to changes in the group’s sales structure with a higher proportion of industrial sales contributing to the overall increase in gross profit margin.
Tianjin Pharmaceutical Da Ren Tang Group has reported earnings of RMB146.14 million ($27.1 million) for the 3QFY2024 ended Sept 30, 8% higher y-o-y. For the 9MFY2024, the group’s earnings, however, fell by 6% y-o-y to RMB803.9 million.
3QFY2024 revenue fell by 3% y-o-y to RMB1.65 billion while 9MFY2024 revenue fell by 3.1% y-o-y to RMB5.61 billion due to a y-o-y decrease in commercial sales.
